[go: up one dir, main page]

MX2010009940A - Variaciones geneticas asociadas con resistencia a drogas. - Google Patents

Variaciones geneticas asociadas con resistencia a drogas.

Info

Publication number
MX2010009940A
MX2010009940A MX2010009940A MX2010009940A MX2010009940A MX 2010009940 A MX2010009940 A MX 2010009940A MX 2010009940 A MX2010009940 A MX 2010009940A MX 2010009940 A MX2010009940 A MX 2010009940A MX 2010009940 A MX2010009940 A MX 2010009940A
Authority
MX
Mexico
Prior art keywords
drug resistance
genetic variations
variations associated
cancer
methods
Prior art date
Application number
MX2010009940A
Other languages
English (en)
Inventor
Mark Lackner
Lukas C Amler
Guy Cavet
Carol O'brien
Ajay Pandita
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010009940(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2010009940A publication Critical patent/MX2010009940A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Métodos y composiciones se proporcionan para determinar si un cáncer es resistente a tratamiento con agentes anti-mitóticos, incluyendo tratamiento con T-DM1. Los métodos se refieren a determinación si el gen ABCC3 se amplifica y/o sobre-expresa en el cáncer.
MX2010009940A 2008-03-14 2009-03-12 Variaciones geneticas asociadas con resistencia a drogas. MX2010009940A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3687408P 2008-03-14 2008-03-14
US5406408P 2008-05-16 2008-05-16
PCT/US2009/036985 WO2009114711A2 (en) 2008-03-14 2009-03-12 Genetic variations associated with drug resistance

Publications (1)

Publication Number Publication Date
MX2010009940A true MX2010009940A (es) 2010-09-28

Family

ID=41010337

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009940A MX2010009940A (es) 2008-03-14 2009-03-12 Variaciones geneticas asociadas con resistencia a drogas.

Country Status (16)

Country Link
US (2) US9879267B2 (es)
EP (1) EP2260111B2 (es)
JP (5) JP2011517555A (es)
KR (2) KR20160066557A (es)
CN (1) CN102027135B (es)
AU (1) AU2009223124B2 (es)
BR (1) BRPI0906049A8 (es)
CA (1) CA2715319A1 (es)
DK (1) DK2260111T3 (es)
ES (1) ES2544682T3 (es)
HU (1) HUE025102T2 (es)
IL (1) IL207538A (es)
MX (1) MX2010009940A (es)
PL (1) PL2260111T3 (es)
SI (1) SI2260111T1 (es)
WO (1) WO2009114711A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
CN102532298B (zh) * 2012-03-01 2013-11-06 刘林林 与自身抗体特异性结合的abcc3抗原多肽及应用
EP2777714A1 (en) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
RS62157B1 (sr) * 2013-11-19 2021-08-31 Remegen Co Ltd Anti-her2 antitelo i njegov konjugat
KR101475032B1 (ko) 2014-06-20 2014-12-23 국립암센터 Her2 저해제 내성 암을 진단하기 위한 마커, 이를 포함하는 진단키트 및 her2 저해제 내성 암을 진단하는 방법
JP7059199B2 (ja) * 2016-04-22 2022-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 細胞成分をマトリックスに結合させるための方法
EP3836967A4 (en) 2018-07-30 2022-06-15 ReadCoor, LLC METHODS AND SYSTEMS FOR SAMPLE PROCESSING OR ANALYSIS
WO2025137394A1 (en) * 2023-12-19 2025-06-26 The General Hospital Corporation Using extracellular vesicles to assess treatment efficacy of antibody-drug conjugate (adc) therapies

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687409A (en) 1971-02-24 1972-08-29 Gen Electric Fastening support means
US5406409A (en) 1994-03-30 1995-04-11 Hoya Corporation Narrow linewidth BBO optical parametric oscillator utilizing extraordinary resonance
KR20020012292A (ko) 1999-06-25 2002-02-15 제넨테크, 인크. 항-ＥｒｂＢ 항체-메이탄시노이드 결합체를 사용한 치료방법
PL203326B1 (pl) * 1999-06-25 2009-09-30 Genentech Inc Przeciwciało, kompozycja farmaceutyczna, koniugat, izolowany kwas nukleinowy, wektor, komórka gospodarza i sposób wytwarzania przeciwciała
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
UA74574C2 (en) 2000-05-02 2006-01-16 Telik Inc Bis (n,n'-bis(2-halogenethyl)amino)phosphodiamates, a method for producing thereof (variants), a pharmaceutical composition containing them, and a method for the treatment of tumors
US20040101834A1 (en) * 2001-03-06 2004-05-27 Yehuda Assaraf Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy
US7115265B1 (en) * 2001-05-14 2006-10-03 Duke University Four genetic tumor markers specific for human glioblastoma
US7767390B2 (en) * 2001-11-20 2010-08-03 Oncomedx, Inc. Methods for evaluating drug-resistance gene expression in the cancer patient
WO2004075842A2 (en) * 2003-02-25 2004-09-10 Dana-Farber Cancer Institute, Inc. Mrp3 genes and uses thereof
BRPI0414812A (pt) * 2003-09-26 2006-11-14 Forbes Medi Tech Inc método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres
DE602004024921D1 (de) 2003-11-17 2010-02-11 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
US20050282910A1 (en) 2003-11-28 2005-12-22 Xun Hu Methods of application of chemical compounds having therapeutic activities in treating cancers
ZA200605822B (en) * 2003-12-16 2009-05-27 Genentech Inc Novel gene disruptions, compositions and methods relating thereto
EP2275448A3 (en) * 2003-12-19 2013-02-06 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
WO2005061707A1 (ja) * 2003-12-24 2005-07-07 Kyowa Hakko Kogyo Co., Ltd. 癌細胞のEg5阻害剤に対する感受性を判定する方法
JP4658967B2 (ja) * 2003-12-24 2011-03-23 ジェネンテック， インコーポレイテッド 造血系起源の腫瘍の治療のための組成物と方法
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
US8178505B2 (en) * 2005-01-05 2012-05-15 Sloan-Kettering Institute For Cancer Research Method of predicting and reducing risk of metastasis of breast cancer to lung
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
AU2006308847C1 (en) * 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
WO2008143702A2 (en) 2006-12-01 2008-11-27 Duke University Anti-mrp3 antibodies and methods of use

Also Published As

Publication number Publication date
ES2544682T3 (es) 2015-09-02
JP2015133963A (ja) 2015-07-27
AU2009223124B2 (en) 2015-03-26
JP2021151231A (ja) 2021-09-30
EP2260111B1 (en) 2015-06-17
KR20100127780A (ko) 2010-12-06
US11021711B2 (en) 2021-06-01
JP6882212B2 (ja) 2021-06-02
AU2009223124A1 (en) 2009-09-17
PL2260111T3 (pl) 2015-11-30
IL207538A0 (en) 2010-12-30
CN102027135B (zh) 2015-04-22
HUE025102T2 (en) 2016-04-28
US20110177099A1 (en) 2011-07-21
US20180298387A1 (en) 2018-10-18
CN102027135A (zh) 2011-04-20
JP2017074036A (ja) 2017-04-20
KR101881168B1 (ko) 2018-07-24
EP2260111B2 (en) 2022-03-23
US9879267B2 (en) 2018-01-30
BRPI0906049A8 (pt) 2018-06-26
JP2011517555A (ja) 2011-06-16
KR20160066557A (ko) 2016-06-10
WO2009114711A3 (en) 2009-11-12
CA2715319A1 (en) 2009-09-17
IL207538A (en) 2013-10-31
SI2260111T1 (sl) 2015-10-30
DK2260111T3 (en) 2015-09-14
JP2018086000A (ja) 2018-06-07
EP2260111A2 (en) 2010-12-15
AU2009223124A2 (en) 2010-09-23
WO2009114711A2 (en) 2009-09-17
BRPI0906049A2 (pt) 2015-07-07

Similar Documents

Publication Publication Date Title
MX2010009940A (es) Variaciones geneticas asociadas con resistencia a drogas.
IL206079A0 (en) Microrna expression profiling and targeting in peripheral blood in lung cancer
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
WO2009154835A3 (en) Compositions and methods related to mir-16 and therapy of prostate cancer
PH12015500485A1 (en) Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
IL201217A0 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
IL202292A0 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
ZA201101132B (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
BRPI0811556A2 (pt) inativação de genes de organismos mesofílicos e termofílicos, e métodos de uso dos mesmos.
BRPI0816150A2 (pt) genes relacionados com câncer, cdca5, eph47, stk31 e w-dhd1.
WO2011005566A3 (en) Aptamer-targeted sirna to inhibit nonsense mediated decay
MX369867B (es) Gen y variaciones asociadas con el fenotipo bm1, marcadores moleculares, y su uso.
WO2005116259A3 (en) Use of gene expression profiling to predict survival in cancer patient
WO2010123982A3 (en) Gene expression signatures associated with resistance to imatinib mesylate
WO2009151590A3 (en) Methods of treating cyp2d6 alternative metabolizers
ZA201205439B (en) Genetic markers associated with drought tolerance in maize
BRPI0909063A2 (pt) Amplificação de alvo e sequenciamento com iniciadores compreendendo unidades monoméricas de formação de tripla.
IL198354A0 (en) Genetic variations associated with tumors
WO2011005384A3 (en) Dna repair or brca1-like gene signature
ATE533861T1 (de) Mipol1-etv1-gen-neuanordnungen
EP2084283A4 (en) DNA MUTANT POLYMERASES AND THEIR GENES
WO2008033782A8 (en) Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker
Potebnya et al. Biotherapy of cancer: achievements and perspectives
AU321365S (en) A pond or a fountain

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration